Document:

Exhibit 10.12

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (the “Agreement”)
is dated and entered into as of June 10, 2016 by and between Accelerated Pharma, Inc., a corporation organized under the laws of
the State of Delaware (the “Company”), and Randy S. Saluck (the “Executive”).

 

WHEREAS, the Executive is currently employed
as the Company’s Chief Financial Officer, Chief Strategic Officer and Secretary; and

 

WHEREAS, the Company desires to continue
to employ the Executive in such capacities, and the Executive desires to continue such employment in such capacities, in each case
on the terms and conditions contained herein.

 

NOW, THEREFORE, in consideration of the
foregoing premises and mutual covenants and agreements herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereby agree as follows:

 

1.           Term of Employment. Subject to
the provisions of Section 5 of this Agreement, the Executive shall be employed by the Company for a period commencing on the date
of the consummation of the Qualified Offering (defined below) (the “Effective Date”) and ending on the third (3rd)
anniversary of the Effective Date (the “Term”). The Term shall be renewed automatically for additional one (1)
year period(s) unless terminated by the Company in writing by notice to Executive delivered no fewer than ninety (90) days prior
to expiration of the then-applicable Term.

 

2.           Position.

 

(a)           Duties. The principal duties of
the Executive shall be to serve in the position of Chief Financial Officer, Chief Strategic Officer and Secretary. In such capacities,
the Executive shall render full time services to the Company as an executive officer of the Company and shall be responsible for
all financial and strategic aspects of the business of the Company, including the preparation and review of the financial operations
of the Company and assisting in the development and implementation of the strategic development plans of the Company, as well as
all tasks and responsibilities normally associated with the offices of Chief Financial Officer, Chief Strategic Officer and Secretary
of clinical stage biotechnology company of similar size and nature to the Company, all subject to the direction and control of
the Board of Directors of the Company (the “Board”) and the Company’s Chief Executive Officer. All references
to the “Board” in this Agreement shall include any committee of the Board (including the Compensation Committee of
the Board) that has been or is in the future delegated the power of the Board to oversee and manage the compensation of the Company’s
officers and employees.

 

(b)           Devotion of Time to Company’s
Business. The Executive shall use his best efforts, skills and abilities to promote and protect the interests of the Company
and devote the substantial portion of his working time and energies to the business and affairs of the Company. Notwithstanding
anything to the contrary contained herein, the Executive (i) may serve on the board(s) of additional companies or organizations
and receive compensation for such services rendered (ii) may engage in charitable, civic, fraternal, professional, trade association
or other activities on behalf of private companies and receive compensation for such services rendered, provided that in each such
case the activities engaged in by the Executive do not materially interfere with his primary obligations to the Company, do not
compete with the Company and do not materially reduce the amount of his working time devoted to the business and affairs of the
Company. All such activities shall be reported to the Board prior to the Executive undertaking such activities (other than those
activities (all of which have been disclosed to the Company by Executive) engaged in as of the Effective Date).

 

    	 	 1	 

     

    

 

(c)           Directors and Officers Liability Insurance.
During the Term and for a period of six years thereafter, the Company, or any successor to the Company resulting from a change
in control, shall maintain a directors and officers liability insurance policy (or policies) in a minimum amount of $5,000,000
which shall provide comprehensive coverage to Executive.

 

(d)           Best Efforts. The Executive shall
use his best efforts to carry out and successfully complete the assignments, tasks and job activities required, from time to time,
to be performed to carry out Executive’s duties and responsibilities during the Term. The Executive’s duties and assignments
shall be undertaken at such location(s) as may be determined from time to time by the Company, but in no event shall Executive
be required to perform his duties on a regular basis at any location more than 25 miles from the location where Executive regularly
performs his duties for the Company immediately prior to the Effective Date.

 

(e)           Company Rules, Policies and Regulations.
The Executive shall, at all times, conduct himself in a professional manner and adhere to the standards, ethical obligations, rules,
policies, regulations and procedures of the Company which are presently in force or which may be established from time to time
by the Company. Executive shall take no intentional action that violates any law, rule or regulation whatsoever while acting in
his capacity as employee.

 

3.           Compensation and Benefits.

 

(a)         Financing Bonus. Upon the consummation
by the Company of a financing or series of related financings in which the Company receives aggregate gross proceeds of $9 million
($9,000,000) (a “Qualified Financing”), the Executive shall be entitled to receive a one-time cash bonus of
$81,900, which shall be paid within 5 business days following the consummation of the Qualified Financing.

 

(b)         Base Salary. As of the Effective
Date, the Executive shall be paid a base salary in consideration for his services provided to the Company at the rate of $325,000
per annum (the “Base Salary”), payable in accordance with the Company’s normal payroll practices. Increases
in Base Salary during the Term shall be determined from time to time in the sole discretion of the Board based upon such criteria
as they deem relevant, or based on no particular criteria whatsoever; provided that, the minimum increase to the Base Salary shall
be 5% per annum.

 

(c)         Additional Compensation. The
Executive shall have an annual bonus target equal to 50% of the then current Base Salary for each calendar year during the Term
(the “Annual Bonus” and, together with the Base Salary, the “Annual Compensation”). The Annual
Bonus shall be determined by the Board in its sole discretion based upon criteria and goals to be established by the Board in consultation
with the Executive and the Company’s other executive officers. The Annual Bonus shall be paid to the Executive on or prior
to the March 15 following the end of the year (other than the bonus set forth in 3(a) above) for which such Annual Bonus was earned;
provided, that if the criteria for determining the Annual Bonus requires a review of the Company’s audited financial statements,
management performance and impact on company’s business plan, the Annual Bonus (if payable) shall be paid no later than the
10th day following the publishing of such audited financial statements (but in no event shall such payment violate Section 409A
(“Section 409A”) of the Internal Revenue Code of 1986, as amended (“Code”). The Executive
also shall be entitled to receive additional cash, equity or other compensation or benefits in consideration for his services provided
to the Company, at such times and in such amounts as shall be determined in the sole discretion of the Board. The Board shall conduct
a review not less than once each year, and such additional compensation, if any, shall be based on, among other things, the Executive’s
and the Company’s performance; provided, that any such additional compensation shall be structured and/or paid in a manner
that avoids or complies with the requirements of Section 409A.

 

    	 	 2	 

     

    

 

(d)          Equity Awards, etc.

 

(i)           As of the consummation of a
Qualified Financing, the Executive shall receive a one-time grant of stock options (the “Initial Option Grant”)
to purchase shares of Company common stock in an amount equal to 0.82% percent of the primary shares of Company common stock outstanding
as of such date. The Initial Option Grant: (A) shall be issued under and be subject to the terms of the Company’s 2016 Equity
Incentive Plan (the “Plan”), (B) will vest in thirty-six (36) equal monthly installments beginning on the one
month anniversary of the the consummation of a Qualified Financing, (C) will have a per share exercise price equal to the Fair
Market Value (as defined in the Plan) of a share of Company common stock on the consummation of a Qualified Financing and (D) shall
provide for cashless exercise (in accordance with the applicable provisions of the Plan); and

 

(ii)          In addition to the other compensation
payable to the Executive hereunder, the Executive shall be entitled to receive grants of stock options, restricted stock and/or
any other equity incentive awards available to senior executives of the Company, under the Plan or any other equity incentive plans
adopted by the Company, at such times and in such amounts as shall be determined in the sole discretion of the Board.

 

(e)          Tax Gross-Up Payment. Upon the
occurrence of a Change in Control (as defined below) of the Company, if all or any portion of the payments provided under this
Agreement and/or any other payments and benefits that the Executive receives or is entitled to receive from the Company or an affiliate
thereof (should the Executive be entitled to the same in accordance with the terms hereof or such other benefits) constitutes an
“excess parachute payment” within the meaning of Section 280G(b)(1) of the Code (each such payment, a “Parachute
Payment”), and would result in the imposition on the Executive of an excise tax under Section 4999 of the Code (“Excise
Tax”), then in addition to any other benefits to which the Executive is entitled under this Agreement, the Company shall
pay the Executive an additional amount in cash (the “Gross-Up Payment”) such that the net amount received by
the Executive in connection with the Change in Control, after payment of (i) any Excise Tax and (ii) any Federal, state and local
income and employment taxes on the Gross-Up Payment by Executive, shall be equal to the aggregate Parachute Payments payable to
the Executive. For purposes of determining the amount of the Gross-Up Payment, the Executive shall be deemed to pay Federal income
tax at the highest marginal rate of Federal income taxation in the calendar year in which the Gross-Up Payment is to be made and
state and local income taxes at the highest marginal rate of taxation in the state or locality of the Executive’s residence
in the calendar year in which the Gross-Up Payment is to be made, net of the maximum reduction in Federal income taxes which could
be obtained from deduction of such state and local taxes. Any Gross-Up Payment due to the Executive under this Section 3(e) shall
be paid to the Executive no later than the end of the year following the year in which the Executive or the Company paid the related
taxes.

 

(f)          Withholding. All salaries, bonuses
and other benefits payable to the Executive shall be subject to payroll, withholding and other taxes or deductions as may be required
by law.

 

4.           Employee Benefits; Business Expenses.

 

(a)          Employee Benefits. During the Term,
the Executive and his dependents shall be entitled to participate in the Company’s healthcare plans, welfare benefit plans,
life insurance plans or policies, fringe benefit plans and any qualified or non-qualified retirement plans as in effect from time
to time (collectively, the “Employee Benefits”), on the same basis as those benefits are made available to the
other senior executives of the Company, in accordance with the Company policy as in effect from time to time and in accordance
with the terms of the applicable plan documents (if any). If at any time the Company does provide a health insurance plan for which
the Executive is eligible, the Executive shall be entitled to reimbursement by the Company of the cost of health insurance paid
by the Executive for the Executive and his family. Any such reimbursement shall be paid to the Executive not later than March 15
of the year following the calendar year in which the Executive paid such cost. To the extent that the Company does not provide
a health insurance plan for which the Executive is eligible, the Executive shall be entitled to reimbursement by the Company of
the cost of health insurance paid by the Executive for the Executive and his family, which reimbursement shall be grossed-up to
cover any taxes the Executive would be required to pay as the result of the Company reimbursing the Executive for the cost of the
Executive’s health plan.

 

    	 	 3	 

     

    

 

(b)          Perquisites. During the Term, the
Executive shall be entitled to receive such perquisites as are made available to other senior executives of the Company in accordance
with Company policies as in effect from time to time.

 

(c)          Expenses. The Executive shall be
entitled to reimbursement for reasonable and necessary business expenses incurred by him in the performance of his duties and responsibilities
hereunder, such expenses to be documented and reimbursed in accordance with the Company’s reimbursement and expenses policies
as in effect from time to time.

 

(d)          Vacation. The Executive shall be
entitled to four (4) weeks paid vacation per annum; provided, that the Executive shall be paid annually in cash for vacation days
not taken by him; provided that no more than four (4) weeks of vacation may be accrued each year for purposes of such cash payments;
and provided further that any such payment shall be paid to the Executive not later than March 15 of the year following the calendar
year in which the unused vacation days accrued.

 

5.           Termination.

 

(a)          Definitions. For purposes of this
Agreement:

 

(i)           “Cause”
shall mean (A) the Executive’s gross negligence and/or willful misconduct (as such terms are generally understood and applied
to the performance of an executive) in the performance of his material duties with respect to the Company as determined, in each
case, by a court of competent jurisdiction not subject to further appeal or a final arbitration award, as provided hereunder, (B)
the conviction by the Executive of a crime constituting a felony or (C) the Executive shall have committed any material act of
malfeasance, disloyalty, dishonesty or breach of fiduciary duty against the Company, for which the Executive shall have a ten (10)
day cure period following notice thereof from the Company (except for a conviction pursuant to subsection (B), for which there
shall be no cure period).

 

(ii)          “Change of Control”
means the occurrence of any one or more of the following events (it being agreed that, with respect to paragraphs (A) and (C) of
this definition below, a “Change of Control” shall not be deemed to have occurred if the applicable third party acquiring
party is an “affiliate” of the Company within the meaning of Rule 405 promulgated under the Securities Act of 1933,
as amended):

 

(A)         An acquisition (whether directly
from the Company or otherwise) of any voting securities of the Company (the “Voting Securities”) by any “Person”
(as the term person is used for purposes of Section 13(d) or 14(d) of the Securities and Exchange Act of 1934, as amended (the
“1934 Act”)), immediately after which such Person has “Beneficial Ownership” (within the meaning
of Rule 13d-3 promulgated under the 1934 Act) of forty percent (40%) or more of the combined voting power of the Company’s
then outstanding Voting Securities; or

 

    	 	 4	 

     

    

 

(B)        The individuals who, as of the
consummation of any transaction or series of related transactions described in paragraphs (A) and (C) of this definition, are members
of the Board cease, by reason of transactions, to constitute at least fifty-one percent (51%) of the members of the Board; or

 

(C)        The consummation, in one or a
series of related transactions, of:

 

(I)           A merger, consolidation or
reorganization involving the Company, where either or both of the events described in clauses (A) or (B) above would be the result;
or

 

(II)           The sale or other disposition
of all or substantially all of the assets of the Company to any Person (other than a transfer to a subsidiary of the Company).

 

(iii)         “Date of Termination”
shall mean the date the Notice of Termination is given to the respective party; provided, however, that with respect to a termination
for Cause by the Company, the Date of Termination shall not occur prior to the expiration of any applicable cure period.

 

(iv)         “Disability”
shall mean the Executive has become physically or mentally incapacitated and is therefore unable for a period of four (4) consecutive
months to perform any of the material elements of his duties hereunder. Any question as to whether the Executive has a Disability
as to which he (or his legal representative) and the Company cannot agree shall be determined in writing by a qualified independent
physician mutually acceptable to the Executive (or his legal representative) and the Company. If the Executive (or his legal representative)
and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians
shall select a third who shall make such determination in writing. The determination of whether the Executive has a Disability,
as made in writing to the Company and the Executive by such physician(s), shall be final and conclusive for all purposes of this
Agreement.

 

(v)          “Good Reason”
shall mean (A) a breach by the Company of any of its material obligations or covenants or change to any of the material terms set
forth in this Agreement, (B) a material reduction of the duties, responsibilities or title of the Executive, (C) the assignment
to the Executive of any duties or responsibilities that are inconsistent, in any significant respect, with his position, for which
the Company shall have a ten (10) day cure period following notice thereof from Executive to the Company, (D) an abandonment of,
or fundamental change in, the primary business or primary products of the Company, (E) a Change of Control, but only if the Executive’s
termination occurs within twelve (12) months after the occurrence of such Change of Control.

 

(vi)         “Notice of Termination”
shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon and shall set forth in
reasonable detail the facts and circumstances claimed to provide a basis for termination of employment under the provision so indicated,
and shall be communicated, in writing, to the other party hereto in accordance with the provisions of Section 10(g) hereof.

 

(b)          By the Company for Cause or by the Executive
Without Good Reason.

 

    	 	 5	 

     

    

 

(i)           The Term and the Executive’s
employment hereunder may be terminated by the Company for Cause, immediately upon the delivery of a Notice of Termination by the
Company to the Executive (except where the Executive is entitled to a cure period hereunder, in which case such Date of Termination
shall be upon the expiration of such cure period if such matter constituting Cause is not cured) and shall terminate automatically
upon the Executive’s resignation (other than for Good Reason or due to the Executive’s death or Disability).

 

(ii)         If the Executive’s
employment is terminated by the Company for Cause, or if the Executive resigns other than for Good Reason, the Executive shall
be entitled to receive:

 

(A)        any earned but unpaid Base Salary
and/or accrued but unused vacation, all vested equity, and any earned but unpaid bonus awards through the Date of Termination,

 

(B)         reimbursement for any unreimbursed
business expenses incurred by the Executive in accordance with the Company’s policy prior to the Date of Termination (with
such reimbursements to be paid promptly after the Executive provides the Company with the necessary documentation of such expenses
to the extent required by such policy but in no event later than the end of the second calendar month following the year in which
the Date of Termination occurred), and

 

(C)        such Employee Benefits, if any,
as to which he may be entitled upon termination of employment under the terms of the plan documents and applicable law (including
under the applicable provisions of Consolidated Omnibus Budget Reconciliation Act of 1985, as amended).

 

Following the Executive’s termination
of employment by the Company for Cause or if he resigns other than for Good Reason, except as set forth above or as required by
applicable law, the Executive shall have no further rights to any compensation or any other benefits or perquisites under this
Agreement and all unvested option or restricted stock grant awards shall immediately be cancelled without the need for any action
by the Company.

 

(c)          By the Company Other Than for Cause
or by the Executive for Good Reason.

 

(i)           The Term and the Executive’s
employment hereunder may be terminated by the Company other than for Cause, immediately upon the delivery of a Notice of Termination
by the Company to the Executive and shall terminate automatically and immediately upon the Executive’s resignation for Good
Reason at the end of any applicable cure period if the circumstances giving rise to Good Reason are not cured.

 

(ii)           If the Executive’s employment
is terminated by the Company other than for Cause, or if the Executive resigns for Good Reason, the Executive shall receive and
the Company shall pay to Executive on the Date of Termination:

 

(A)        any earned but unpaid Base Salary
and/or accrued but unused vacation, all vested equity, and any earned but unpaid bonus awards through the Date of Termination,
plus an additional twelve (12) months of Annual Compensation (other than the case of a Change of Control, in which case the payment
shall be an additional eighteen (18) months of Annual Compensation), together in a lump sum payment;

 

    	 	 6	 

     

    

 

(B)         acceleration of any then-unvested
stock options, restricted stock grants or other equity awards;

 

(C)         payment or reimbursement, as
applicable, of the full health insurance costs for the Executive and his family under a Company-provided group health plan or otherwise
for twenty-four (24) months following termination by the Company other than for Cause or resignation by Executive for Good Reason,
provided that any such payment or reimbursement which constitutes deferred compensation under Section 409A shall be made annually
within thirty (30) days after the end of the calendar year in which the health insurance costs were incurred;

 

(D)         in the event any bonus or other
form of additional compensation is paid to any other executive(s) of the Company for the fiscal year during which Executive’s
employment ceased pursuant to this Section 5(c), a cash amount equal to the largest bonus or other form of additional compensation
payment made by the Company to any other executive of the Company during such fiscal year, provided that in the event such bonus
or other form of compensation is not ascertainable on the Date of Termination, such payment shall be made no later than March 15
of the year following the calendar year in which the Date of Termination occurred;

 

(E)         reimbursement for any accrued
but unused vacation days and/or unreimbursed business expenses incurred by the Executive in accordance with the Company’s
policy prior to the Date of Termination (with such reimbursements to be paid promptly after the Executive provides the Company
with the necessary documentation of such expenses to the extent required by such policy but in no event later than the end of the
second calendar month following the year in which the Date of Termination occurred); and

 

(F)         such other Employee Benefits,
if any, as to which he may be entitled upon termination of employment hereunder.

 

Following the Executive’s termination
of employment by the Company other than for Cause or if he resigns for Good Reason, except as set forth above or as required by
applicable law, the Executive shall have no further rights to any compensation or any other benefits under this Agreement. Notwithstanding
the foregoing, in order to be eligible for any of the severance payments and benefits under this Section 5(c), the Executive must
execute and deliver to the Company a general release in a form reasonably satisfactory to the Board. If the payments to be made
under this Section 5(c) are otherwise subject to Section 409A, they shall be made, or commence to be made, on the first pay period
following the date that is thirty (30) days after the Executive’s employment terminates. If the payments are not otherwise
subject to Section 409A, they shall be made, or commence to be made, on the first business day after the release becomes effective.
The initial payment shall include any unpaid amounts from the date the Executive’s employment terminated, subject to the
Executive’s executing and delivering the release on the terms as set forth above.

 

(d)           Death or Disability. The Executive’s
employment hereunder shall terminate upon the Executive’s death and may be terminated by the Company, within ten (10) days
after the delivery of a Notice of Termination by the Company to the Executive (or his legal representative) in the event of the
Executive’s Disability. Upon termination of the Executive’s employment hereunder for either Disability or death, the
Executive shall be entitled to receive the same payments and other items as set forth in clause (ii) of Section 5(b) hereof, except
that Executive (in case of Disability) or the estate (in the event of death) shall have the right to exercise any unexercised and
vested options for a period of 90 days, and, in addition, to receive payment for accrued but unpaid vacation time, if any. Following
the Executive’s termination of employment due to death or Disability, except as set forth herein or as required by applicable
law, the Executive (nor his estate) shall have no further rights to any compensation or any other benefits under this Agreement.

 

    	 	 7	 

     

    

 

(e)          Payment of Amounts Owed upon Termination
of Employment. Unless otherwise provided herein, any amounts payable to the Executive for earned but unpaid Base Salary and
cash, equity or other bonus awards through the Date of Termination shall be paid within ten (10) business days after the Date of
Termination.

 

6.           Restrictive Covenants.

 

(a)          Definitions.

 

(i)          “Confidential Information”
means all confidential and proprietary of, about, or relating to the Company and the Company Business, including, without limitation,
any and all documents received or generated by Executive, existing and potential customer lists, trade secrets (as defined under
applicable state law), pricing, financial, corporate, and personnel information, customer data, methods of operation, business
plans, techniques, prototypes, sketches, drawings, models, inventions, know-how, processes, apparatus, software programs, computer
codes, source codes, equipment, algorithms, source documents, formulae, methods, data, descriptions relating to current, future,
and proposed products and services, information concerning research, experimental work, development, specifications, engineering,
procurement requirements, purchasing, agents and suppliers, business forecasts, marketing plans and information received from third
parties (including customers) that is subject to a duty on Executive’s part to maintain its confidentiality. Confidential
Information does not include information that is generally known to the public, provided it is generally known to the public other
than as a result of disclosure of such information by Executive in violation of this Agreement.

 

(ii)          “Commercial Partner”
means each third party person or entity with whom Executive interacts on behalf of the Company during the term of his employment
with the Company, whether pursuant to this Agreement or otherwise, including, without limitation, licensors, licensees, contract
research organizations, contract sales organizations and joint venture partners; provided that, on the date of the termination
of Executive’s employment with the Company, Commercial Partner shall mean those third party persons and entities with whom
Executive interacted on behalf of the Company during the Lookback Period.

 

(iii)         “Company Business”
means the business(es) engaged in by the Company, from time to time during the term of Executive’s employment with the Company,
whether pursuant to this Agreement or otherwise; provided that, on the date of the termination of Executive’s employment
with the Company, the Company Business shall be the business(es) engaged in by the Company during the Lookback Period.

 

(iv)         “Former Employee”
means any person who has been employed or engaged as an independent contractor by the Company during the Look Back Period.

 

(v)         “Former Commercial
Partner” means each third party person or entity who is not a Commercial Partner but was a Commercial Partner during
the Look Back Period.

 

(vi)        “Look Back Period”
means the two (2) year period immediately preceding the earlier of: (1) the date on which the definition in question is being determined;
or (2) the date when Executive is no longer employed by the Company, whether pursuant to this Agreement or otherwise.

 

    	 	 8	 

     

    

 

(vii)       “Prospect”
means each person or entity who is not a Commercial Partner, and for whom, at any time during the Look Back Period, the Company,
whether through its employees, contractors or vendors, expended directed marketing efforts or undertook other business development
efforts which resulted in at least an indication of interest from such person or entity of becoming a Commercial Partner.

 

(viii)      “Territory”
means the United States and their respective territories and commonwealths.

 

(b)         Non-Solicitation, Non-Competition and
Non-Piracy. For the term of Executive’s employment, whether under this Agreement or otherwise, and for a period of one
(1) year after the cancellation, termination or expiration of Executive’s employment with the Company (the “Restriction
Period”), by whatever means and for whatever reason, Executive shall not, directly or indirectly, individually, or jointly
with others, for the benefit of Executive or any third party:

 

(i)          have any equity or other ownership
interest in, or become a director or manager of, or be otherwise associated with, or engaged or employed by, any Commercial Partner,
Prospect or Former Commercial Partner or their subsidiary or parent entities or affiliates in any job or career that relates to
or concerns any activity substantially similar, in whole or in part, to the Company Business;

 

(ii)         solicit, render services to,
or accept business from any Commercial Partner or Prospect or any of their subsidiary or parent entities or affiliates for any
business activity that relates to or concerns any activity substantially similar, in whole or in part, to the Company Business;
provided that Executive shall not be bound by the foregoing with respect to persons to whom Executive has made sales or otherwise
provided products and services prior to the date hereof; and provided further, however, if this Agreement is terminated pursuant
to Section 5(c), the restrictive covenant contained in this subsection shall only apply if Employee had ever received the Base
Salary and then only for so long as Employee receives payments under Section 5(c) in a timely manner; and

 

(iii)        solicit, hire, compensate
or engage as an employee, agent, contractor, shareholder, member, joint venturer, or consultant, whether or not for consideration,
any of the Company’s employees or otherwise induce any of the Company’s employees, subcontractors or vendors to change
their relationship with the Company.

 

(c)         Confidentiality. Executive shall
never: (i) disclose to any individual or entity any Confidential Information; and (ii) directly or indirectly give or permit any
individual or entity to have access to any Confidential Information; and (iii) make any use, commercial or otherwise, of any Confidential
Information, except, solely as reasonably required to perform Executive’s employment duties with the Company and solely for
the benefit of the Company.

 

(d)         Tolling of Restriction Period. In
the event of Executive’s breach of one or more of the provisions of this section, the running of the Restriction Period shall
be tolled during the continuation of such breach(es) and recommence only upon Executive’s full and complete compliance with
the provisions of this Section 6.

 

    	 	 9	 

     

    

 

(e)           Judicial Modification. In the event
a court of competent jurisdiction holds one or more of the provisions of the restrictive covenants invalid as to length of time
or geographic scope, then this Section 6 shall be amended to reflect a different length of time and/or geographic scope.

 

7.           Works for Hire and Intellectual Property.
Executive acknowledges and agrees that: (a) all Work Product (as defined below) that so qualifies shall be deemed a “work
for hire” for all purposes and the property of the Company; and (b) he hereby assigns all of his intellectual property and
other rights in all other Work Product to the Company. All right, title and interest in and to, and the right to pursue protection
for, Work Product shall vest solely with the Company. Upon request by the Company, Executive shall use all reasonable efforts to
assist the Company in securing any intellectual property protection for Work Product and shall execute all documents reasonably
necessary to effect an assignment as contemplated herein. No license is granted to Executive in, to or under any Work Product or
other intellectual property (including, but not limited to, patents, trade secrets, copyrighted materials and trademarks) owned,
licensed or otherwise assertable by Executive by express or implied grant, estoppel or otherwise, except for a limited right to
use any such intellectual property solely in the performance of Executive’s employment duties and solely for the benefit
of the Company. All benefits from the use of any such intellectual property, including Work Product, shall inure solely to the
Company. “Work Product” means all tangible or intangible works: (X) (1) created, produced or modified during
or in connection with Executive’s employment by the Company; or (2) which are related to, or that can be utilized in, the
Company Business; and (Y) that could qualify as the subject matter of a copyright, patent, trade secret or any other form of intellectual
property; and shall include, without limitation, all work produced by or for the benefit of the Company, any Company Affiliated
Party, Commercial Partners, Former Commercial Partners and Prospects

 

8.           Company Property. Executive agrees
that all Company Property (as defined below) is the property solely of the Company and Executive waives and relinquishes any and
all interests or property rights he or she may have therein in favor of the Company. Executive shall immediately return all of
the Company Property to the Company at the Company’s address or such other location as may be directed by the Company upon:
(A) the Company’s request at any time; and (B) upon the termination of Executive’s employment. “Company Property”
includes, but is not limited to: (X) records relating to Commercial Partners, Former Commercial Partners, Prospectus and Confidential
Information in whatever form they exist, and by whomever prepared, including, but not limited to, notes of Executive; (Y) tangible
embodiments of or containing Work Product or Confidential Information; and (Z) tangible and intangible property pertaining to the
Company Business or arising out of or used by Executive in the performance of his duties for the Company.

 

9.           Independent Covenants; Scope and Injunctive
Relief. Executive acknowledges and agrees that the provisions of sections 6, 7 and 8 hereof are independent covenants and no
actual or alleged breach by the Company of any provision of this Agreement or the employment relationship shall be grounds for
relieving Executive from his or her obligations thereunder. The parties acknowledge and agree that the provisions of sections 6,
7 and 8 are necessary and reasonable to protect the legitimate business interest of the Company and any violation of the provisions
of such sections will result in irreparable injury to the Company, the exact amount of which will be difficult to ascertain, and
that the remedies at law for any such violation would not be reasonable or adequate compensation to the Company for such violation.
Accordingly, Executive agrees that if the provisions of sections 6, 7 or 8 are violated, in addition to any other remedy which
may be available in equity or at law, the Company shall be entitled to specific performance and injunctive relief, without the
necessity of proving actual damages or posting bond.

 

    	 	 10	 

     

    

 

10.         Miscellaneous.

 

(a)           Governing Law. This Agreement shall
be construed and governed under and by the laws of the State of Connecticut, without regard to the conflicts of laws principles
thereof.

 

(b)           Arbitration of Claims. In the event
of any dispute, claim, question or disagreement arising from or relating to this Agreement or the breach thereof (and except for
cases in which the Company is entitled to injunctive or other equitable relief as described in Section 9 hereof), the Company and
Executive agree to settle the dispute, claim, question or disagreement by arbitration before a single arbitrator in Connecticut
selected by, and such arbitration to be administered by, the American Arbitration Association (“AAA”) in accordance
with its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator may be entered in any court having
jurisdiction thereof. Each of the Company and Executive hereby agrees and acknowledges that all disputes between or among them
are subject to the alternative dispute resolution procedures of this Section 10(b). Each of the Company and Executive agrees that
any aspect of alternative dispute resolution not specifically covered in this Agreement shall be covered, without limitation, by
the applicable AAA rules and procedures. Each of the Company and Executive further agree that any determination by the arbitrator
regarding any dispute, claim, question or disagreement arising from or relating to this Agreement shall be final and binding upon
the parties hereto and shall not be subject to further appeal. Each of the Company and Executive shall bear its own costs and expenses
and an equal share of the arbitrator’s fees and administrative fees of arbitration; provided, however, that upon receipt
of the determination by the arbitrator the prevailing party shall have all reasonable out-of-pocket fees and expenses reimbursed
promptly (in all events within 10 calendar days following delivery to both parties of the arbitrator’s decision) by the non-prevailing
party in any such dispute.

 

(c)           Entire Agreement; Amendments. This
Agreement sets forth the entire understanding of the parties concerning the subject matter of this Agreement and incorporates all
prior negotiations and understandings. There are no covenants, promises, agreements, conditions or understandings, either oral
or written, between them relating to the subject matter of this Agreement other than those set forth herein. The publication, amendment,
supplementation or replacement of an employee handbook by the Company shall not be deemed to alter, amend or modify the terms and
conditions of this Agreement. No alteration, amendment, change or addition to this Agreement shall be binding upon any party unless
in writing and signed by the party to be charged. No purported waiver by any party of any default by another party of any term
or provision contained herein shall be deemed to be a waiver of such term or provision unless the waiver is in writing and signed
by the waiving party. No such waiver shall in any event be deemed a waiver of any subsequent default under the same or any other
term or provision contained herein. This Agreement may not be altered, modified, or amended except by written instrument signed
by the parties hereto.

 

(d)           No Waiver. No waiver of any of the
provisions of this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed or be construed as
a further, continuing or subsequent waiver of any such provision or as a waiver of any other provision of this Agreement. No failure
to exercise and no delay in exercising any right, remedy or power hereunder will preclude any other or further exercise of any
other right, remedy or power provided herein or by law or in equity.

 

(e)           Severability. If any term or provisions
of this Agreement, or the application thereof to any person or circumstance, shall be invalid or unenforceable, the remainder of
this Agreement, or the application of such term or provision to persons or circumstances, other than those as to which it is held
invalid, shall both be unaffected thereby and each term or provision of this Agreement shall be valid and be enforced to the fullest
extent permitted by law.

 

    	 	 11	 

     

    

 

(f)           Assignment. This Agreement, and
all of the Executive’s rights and duties hereunder, shall not be assignable or delegable by the Executive; provided, however,
that if the Executive shall die, all amounts then payable to the Executive hereunder shall be paid in accordance with the terms
of this Agreement to the Executive’s devisee, legatee or other designee or, if there be no such devisee, legatee or designee,
to his estate. The Company and its successors and assigns may, at any time and from time to time, assign its rights and obligations
under this Agreement, including, without limitation, the rights arising pursuant to sections 6, 7 and 8, without Executive’s
consent in connection with a Change of Control. Upon such assignment, the rights and obligations of the Company hereunder shall
become the rights and obligations of such affiliate or successor person or entity.

 

(g)           Notices. For the purpose of this
Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been
duly given when delivered by hand or internationally recognized courier service addressed to the respective addresses set forth
below in this Agreement, or via facsimile or email transmission to the number or email address set forth below, or to such other
address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address
shall be effective only upon receipt.

 

If to the Company:

 

Accelerated Pharma, Inc.

15w155 81st Street

Burr Ridge, IL 60527

Attention: Chief Executive Officer

Email: mfonstein@apipharmaceuticals.com

 

If to the Executive:

 

Randy S. Saluck

10 Mortar Rock Road

Westport, Ct 06880

Email: rsaluck@apipharmaceuticals.com

 

(h)           Prior Agreements. This Agreement
supersedes all prior agreements and understandings (including verbal agreements) between the Executive and the Company regarding
the terms and conditions of the Executive’s employment with the Company.

 

(i)           Cooperation. The Executive shall
provide his reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which
relates to events occurring during the Executive’s employment hereunder, but only to the extent the Company requests such
cooperation with reasonable advance notice to the Executive and in respect of such periods of time as shall not unreasonably interfere
with the Executive’s ability to perform his duties with any subsequent employer; provided, however, the Company shall pay
any reasonable travel, lodging and related expenses that the Executive may incur in connection with providing all such cooperation,
to the extent approved by the Company prior to incurring such expenses.

 

(j)           Execution and Counterparts. This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or
by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

    	 	 12	 

     

    

 

(k)           Survival. Sections 6, 7, 8 and 10
shall survive the termination, cancellation or expiration of this Agreement by whatever means for whatever reason.

 

(l)           Section 409A.

 

(i)           The parties intend that the
payments and benefits provided for in this Agreement either be exempt from Section 409A, or be provided in a manner that complies
with Section 409A and any ambiguity herein shall be interpreted so as to be consistent with the intent of this paragraph. In no
event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on the Executive by
Section 409A or damages for failing to comply with Section 409A. Notwithstanding anything contained herein to the contrary, all
payments and benefits which are payable upon a termination of employment hereunder shall be paid or provided only upon those terminations
of employment that constitute a “separation from service” from the Company within the meaning of Section 409A (determined
after applying the presumptions set forth in Treas. Reg. Section 1.409A-1(h)(1)). Further, if the Executive is a “specified
employee” as such term is defined under Section 409A at the time of a termination of employment and the deferral of the commencement
of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to
prevent any accelerated recognition of income or additional tax under Section 409A, then the Company will defer the commencement
of the payment of any such payments or benefits hereunder (without any reduction in payments or benefits ultimately paid or provided
to the Executive) until the date that is at least six (6) months following the Executive’s termination of employment with
the Company (or the earliest date permitted under Section 409A, e.g., immediately upon the Executive’s death), whereupon
the Company will promptly pay the Executive a lump-sum amount equal to the cumulative amounts that would have otherwise been previously
paid to the Executive under this Agreement during the period in which such payments or benefits were deferred. Thereafter, payments
will resume in accordance with this Agreement.

 

(ii)           Notwithstanding anything to
the contrary in this Agreement, in-kind benefits and reimbursements provided hereunder during any calendar year shall not affect
in-kind benefits or reimbursements to be provided in any other calendar year, other than an arrangement providing for the reimbursement
of medical expenses referred to in Section 105(b) of the Code, and are not subject to liquidation or exchange for another benefit.
Notwithstanding anything to the contrary in this Agreement, reimbursement requests must be timely submitted by the Executive and,
if timely submitted, reimbursement payments shall be promptly made to the Executive following such submission, but in no event
later than December 31st of the calendar year following the calendar year in which the expense was incurred. In no event shall
the Executive be entitled to any reimbursement payments after December 31st of the calendar year following the calendar year in
which the expense was incurred. This paragraph shall only apply to in-kind benefits and reimbursements that would result in taxable
compensation income to the Executive.

 

(iii)         Additionally, in the event
that following the date hereof the Company or the Executive reasonably determines that any compensation or benefits payable under
this Agreement may be subject to Section 409A, the Company and the Executive shall work together to adopt such amendments to this
Agreement or adopt other policies or procedures (including amendments, policies and procedures with retroactive effect), or take
any other commercially reasonable actions necessary or appropriate to (x) exempt the compensation and benefits payable under this
Agreement from Section 409A and/or preserve the intended tax treatment of the compensation and benefits provided with respect to
this Agreement or (y) comply with the requirements of Section 409A.

 

[Signature Page Follows]

 

    	 	 13	 

     

    

 

IN WITNESS WHEREOF, the parties hereto
have duly executed this Agreement as of the day and year first above written.

 

	 	ACCELERATED PHARMA, INC.
	 	 	 
	 	By:	/s/ Michael Fonstein
	 	 	Name: Michael Fonstein
	 	 	Title: Chief Executive Officer
	 	 	 
	 	EXECUTIVE:
	 	 
	 	/s/ Randy S. Saluck
	 	Randy S. Saluck

 

    	 	 14Exhibit 10.13

 

MASTER SERVICES AGREEMENT

 

This Master Services Agreement
(the “Agreement”) is entered into as of April 27th, 2015 (the “Effective Date”) by and between Accelerated
Pharma Inc. with a place of business at 15W15581st, Burr Ridge 60527 Illinois, USA (“Accelerated”),
and Heraeus Precious Metals GmbH & Co. KG, a German limited liability company with a principal place of business located
at Heraeusstr. 12- 14, 63450 Hanau, Germany (“Manufacturer” or “Heraeus”), each singly a “Party”
and together, the “Parties.”

 

RECITALS

 

Accelerated intends to entrust Heraeus with
the manufacture of the active pharmaceutical ingredient Picoplatin which is required by Accelerated for a clinical development
program.

 

NOW, THEREFORE, the Parties agree as follows:

 

AGREEMENT

 

1             DEFINITIONS.
Throughout this Agreement, the following terms will be defined thus:

 

		1.1	“Affiliates” means any company, firm, individual,
partnership or other legal entity which controls, or is controlled by, or controlled in common with a Party. “Control”
here means holding more than 50% of the nominal value of the issued share capital or of the voting power at the general meeting
of shareholders or members or has the power to appoint a majority of the directors or otherwise directs the activities of such
company, firm, partnership or other legal entity.

 

		1.2	“Confidential Information” is defined in Section
6 below.

 

		1.3	“Day” or “Days” means a calendar
day or days. “Business Days” are weekdays, excepting legal holidays and local holidays in Germany and/or Hessen.

 

		1.4	“Order” means a purchase order for the Products
and services, as further described below, pursuant to this Agreement.

 

		1.5	“Person” means any individual, partnership,
company, firm, legal entity, trust, trustee or association.

 

		1.6	“Personnel” means the employees of a Party,
individuals working as subcontractors of a Party, and employees of such Party’s affiliates, contractors and agents.

 

		1.7	“Product” means the active pharmaceutical ingredient
Picoplatin as described in Annex 1. 1.8 “Specifications” means the technical criteria described in Annex 1.

 

		1.9	Other definitions are found within the Agreement next to
the term defined.

 

2.            SERVICES

 

Manufacturer will provide Services and Products according to Order(s)
made from time to time by both Parties in writing. The Initial Services are described in Annex 1. Each Order, confirmed by the
Manufacturer in writing, executed pursuant to this Agreement shall form a separate agreement between the Parties and be governed
by the terms of this Agreement as if contained therein in their entirety. In the event of any conflict between the terms of this
Agreement and any particular Order, the terms of this Agreement shall take precedence.

 

    	 	 	 

     

    

 

2.1          Manufacturing Services. By signing
this Agreement, Heraeus is entrusted to manufacture three (3) validation batches under CGMP conditions and to deliver these batches
to Accelerated for their clinical development program. A validation batch contains at least 500g of the Product. If Accelerated
requires further validation batches, Accelerated may order further validation batches or GMP batches of the Product at a later
point in time. Each batch shall consist of a minimum quantity of 500g. By signing this Agreement, Heraeus is also entrusted to
create a GMP documentation as well as to conduct a stability study for the Product.

 

2.2          Shipping, Title and Risk of Loss.
The Products will be shipped, Ex Works per Incoterms the Manufacturer’s loading dock, such that title to and risk of loss
in all Product will pass to the Accelerated at the point of shipment using the Accelerated’ s carrier account noted on the
Order. Orders shall be shipped at a mutually agreed upon date and time. After written notice from Accelerated, Manufacturer will
promptly ship the quantities of any missing Product to remedy any shortage.

 

2.3          Delivery. Manufacturer will ensure
Products are packaged sufficiently to maintain their integrity during transportation.

 

2.4          Acceptance. Products will be
deemed accepted upon delivery unless Accelerated makes a rejection of the Products within thirty (30) days of arrival at Accelerated’
s designated destination. Claims for shortages, damage, or obvious defects must be made in writing within that time period. Accelerated
shall not unreasonably reject Products that conform to specifications.

 

2.5          Title. Title and risk of loss
to the Products shall pass to Accelerated at the time Products are delivered to Accelerated. However, Manufacturer retains a security
interest on Products until payment in accordance with this Agreement.

 

2.6          Additional Services. Parties
may agree to contract for additional services than those described in 2.1. Such agreement will be pursuant to a request for quote
(“Request for Quote”) provided by Accelerated to Manufacturer. The Request for Quote will provide sufficient detail
to allow the Manufacturer to proceed with each individual manufacturing project, including details on validation protocols, Accelerated’
s production needs and forecasts, if any, and other details as provided.

 

2.7          Additional Terms. Additional
terms pertaining to shipment of products, delays, risk of loss, insurance, and other terms not provided in this Agreement will
be according to Manufacturer’s terms and conditions of sale (The “Heraeus Terms and Conditions of Sale”), as
then in effect. (The current terms are specified in Annex 2) If there is a conflict between the Agreement and the Heraeus Terms
and Conditions of Sale, then this Agreement will govern.

 

3.            PRICING AND PAYMENT

 

3.1          Pricing for Initial Services
are described in Annex I. The prices for Products ordered by Accelerated at a later point in time are set forth in Heraeus’
offer which Heraeus will send to Accelerated, if and when required. The prices to be paid to Heraeus are exclusive of any statutory
value-added tax as well as exclusive of any other taxes, Pricing duties and charges.

 

    Page 2 of 10 

     

    

 

3.2          If not agreed otherwise agreed
in writing Payment terms for products and services will be Net 30 days after the date of invoice or date of delivery, whichever
occurs later. Invoicing requirements, if any, will be as specified in a mutually agreed electronic format, or if there is no such
format, in the applicable Order.

 

4.            QUALITY

 

4.1          Product Changes

 

4.1.1      Accelerated Proposed Product Changes.
Accelerated may propose changes to any of the Products by submitting such changes to Manufacturer. Accelerated will identify those
changes that it deems mandatory in order to make the Product suitable for Accelerated’s intended use. Unless otherwise agreed
to in writing by Accelerated, Manufacturer will respond in writing to Accelerated within ten (10) Days after receipt of such proposed
or mandatory changes with the following information, as applicable: (i) lead time required to implement the changes, provided that
it is technically feasible; (ii) impact of changes on Product, including, but not limited to, any Parts, tooling, and testing,
and additional costs; (iii) impact of changes on scrap material and work in process; (iv) any non-recurring engineering changes
required in order to implement the changes; and (v) impact of changes on the lead time of the Product.

 

4.1.2      Manufacturer Proposed Product Changes.
Any changes proposed by Manufacturer, including material or process changes, which affect form, fit, function, reliability, serviceability,
performance, functional interchange-ability, regulatory compliance, safety, must be submitted along with a written change notice,
for Accelerated approval. This may include, but is not limited to, changes of sources of material and parts, changes in accepted
manufacturing range, manufacturing processes, test procedures, or replacement of equipment. No such changes may be implemented
by Manufacturer without receiving Accelerated’s prior written approval.

 

4.2          Quality Management System.

 

4.2.1       Manufacturer shall document, implement,
and maintain an acceptable Quality System. Manufacturer will test and inspect all Products in accordance with its existing procedures
before shipping any Products to Accelerated. Manufacturer will supply an Accelerated -approved certificate of compliance for all
Products shipped, which includes the results of the standard testing and procedures. Manufacturer will document all of its standard
operating procedures, including quality assurance, manufacturing, testing and delivery and make copies of those procedures available
to Accelerated for its review and audit.

 

4.2.3       In the event that any Product
fails to meet the specifications, whether discovered prior to delivery or after, Manufacturer will investigate such failure and
document the nature and root cause of the failure. Manufacturer will devise proposed changes to its processes and procedures as
needed in order to avoid repetition of known failures.

 

    Page 3 of 10 

     

    

 

5.            CONFIDENTIALITY

 

5.1          Disclosure and Use of Confidential
Information. In the course of performing or receiving Services in connection with this Agreement, the Manufacturer or Accelerated
(each, when receiving information, the “Receiving Party”) may be given or have access to, confidential and proprietary
information as defined as Confidential Information of the other Party below (the “Disclosing Party”). The Disclosing
Party’s affiliates, subsidiaries, independent contractors, business partners, and licensors, may disclose information relating
to any or all of the Disclosing Party’s products and/or services (whether marketed or in development), business proposals,
manufacturing and distribution processes, customer lists, computer software and related documentation, financial information, and
employee data, whether tangible or intangible, and including all copies, analyses and derivatives thereof, that is marked or otherwise
identified as proprietary or confidential at the time of disclosure, or which if disclosed orally is confirmed in writing by the
Disclosing Party to the Receiving Party within thirty (30) days of initial disclosure (collectively, “Confidential Information”).
The Receiving Party shall not, without the Disclosing Party’s prior written consent, disclose to any third-party any Confidential
Information or use any Confidential Information for any purpose other than performance of the Services. The Receiving Party shall
employ the same standard of care in protecting disclosed Confidential Information as it would employ to protect its own confidential
information, but shall in no event use less than reasonable care. The Receiving Party shall disseminate Confidential Information
to its personnel and Suppliers only on a “need-to-know” basis. The Receiving Party shall cause each of its personnel
and Suppliers who have access to Confidential Information to comply with the terms of this Section 6 in the same manner
as it is bound by this Section 6, with the Receiving Party remaining responsible for the actions and disclosures of any
such personnel.

 

5.2          Exceptions to Confidential Information.
For purposes hereof, “Confidential Information” does not include information that (i) was rightfully in the Receiving
Party’s possession without restriction before disclosure hereunder, (ii) was or becomes public knowledge through no fault
of the Receiving Party, (iii) was rightfully disclosed to the Receiving Party without restriction by a third-party not bound by
a confidentiality restriction, or (iv) was independently developed by the Receiving Party or its personnel. The restrictions in
this Section 6 shall not prevent disclosures required by law, court order or other governmental order or demand; provided
that, to the extent practicable, the Receiving Party provides prompt written notice and reasonable assistance to the Disclosing
Party prior to such disclosure, so that the Disclosing Party may seek a protective order or other appropriate remedy to protect
against or limit such disclosure. The confidentiality obligations set forth in this Agreement shall expire five (5) years from
the date of the disclosure.

 

6.            REPRESENTATIONS

 

6.1          Compliance with Laws. Manufacturer
represents and warrants that Manufacturer shall comply with all applicable laws and regulations and customer policies in which
the Services will be provided, including the maintenance of necessary government permits, licenses and other means by which to
lawfully perform Services. Manufacturer further represents and warrants that no action (or failure to take action) by it or any
of its employees will cause Accelerated to violate or incur any penalty under any applicable law or regulations. Manufacturer does
not assume any liability for the non-infringement of any third-party rights by the manufacture, the placing on the market or the
use of the Product. It shall be the sole responsibility of Accelerated to perform a Freedom to Operate Analysis to ensure that
the Product in the application intended by Accelerated does not infringe any third-party rights.

 

6.2          No Other Restrictive Arrangement.
Manufacturer is not subject to, or a party to, any employment agreement, non-competition covenant, non-disclosure agreement, or
other agreement, covenant, understanding, or restriction that would prohibit Manufacturer from executing this Agreement and performing
fully the duties and responsibilities hereunder.

 

6.3          Disclosure. A Party shall within
three (3) calendar days notify the other Party in the event any representation or warranty by the Party set forth in this Agreement
shall no longer be true, correct, or complete.

 

    Page 4 of 10 

     

    

 

6.4          Conflict
of Interest. Manufacturer covenants that, during the term of this Agreement, Manufacturer will not engage, directly or
indirectly, in any activity that materially conflicts with Manufacturer’s faithful performance of the Services.

 

6.5          Representations and Indemnifications
of Accelerated. Accelerated represents and warrants that Accelerated has all IP rights required for the manufacture, the placement
on the market and the use of the Product in the application intended by Accelerated. In addition, Accelerated represents and warrants
that Accelerated rightfully acquired any and all rights to the manufacturing process of the Product from Poniard Inc. and that
Accelerated is entitled to exercise these IP rights. Accelerated will, upon first written request, indemnify and hold Manufacturer
harmless from and against any and all claims which are asserted or entered against Manufacturer by any third party on account of
the alleged or actual infringement of third party IP rights by the manufacture and/or delivery and/or use of the Product in pharmaceutical
products of Accelerated or third parties. Accelerated shall reimburse to Heraeus any and all damages accruing to Heraeus on account
of such alleged or actual infringement of third-party property rights by the manufacture and/or delivery to Accelerated.

 

7.            WARRANTY AND LIABILITY

 

7.1          Warranty

 

7.1.1       Limited Warranty. Manufacturer
warrants that the Products will be free from defects in workmanship and materials and will conform to the specifications set forth
in Annex 1 for a period of ninety (90) days from the date of receipt by Accelerated (the “warranty period”).

 

7.1.2       Subject to Section 5.1.4,
the Manufacturer’s responsibility for defective or non-conforming Products is limited, at Manufacturer’s option,
to either replacement of the defective Products or return to Accelerated of monies actually
received by Manufacturer from Accelerated for those defective Products, less any unrecoverable costs for components or sub-assemblies.
Manufacturer may require inspection of the defective or non-conforming Products. However, no Product may be returned to Manufacturer
unless such returned Product shall first have been determined to be defective or non-conforming.

 

7.1.3       Accelerated will pay Manufacturer
the cost of all charges, including but not limited to a reasonable charge for examination and rework if the returned Products
prove not to be defective or for work requested by Accelerated that exceeds Manufacturer obligations under this Warranty.

 

7.1.4       This Warranty extends only to
the original customer of the Products (that is, Accelerated). This Warranty does not apply to, and Manufacturer assumes no responsibility
for, damage or defects due to any cause other than those specified above, including, but not limited to, damage or defects arising
as a result of misuse, improper installation by Accelerated’s personnel or subcontractors, accident, neglect, modification,
repair by Accelerated, adverse conditions, and demands exceeding performance levels required by applicable specifications by Manufacturer.
Provision of Products to any third-party terminates this warranty, even though the warranty period has not expired, unless tests
Products against specifications using tests or methods acceptable to Manufacturer prior to that incorporation. In no case, however,
shall the warranty extend beyond the 90-day warranty period.

 

    Page 5 of 10 

     

    

 

7.1.5       THIS
WARRANTY IS EXCLUSIVE AND MADE IN LIEU OF ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. NO MODIFICATION OR ALTERATION OF THE FOREGOING WARRANTY AND LIMITATION
OR REMEDIES PROVISIONS SHALL BE VALD OR ENFORCEABLE UNLESS SET FORTH IN A WRITTEN AGREEMENT SIGNED BY HERAEUS AND THE
CUSTOMER.

 

8.            LIMITATION OF LIABILITY. EXCEPT IN
THE CASE OF BREACH OF CONFIDENTIALITY, IN NO EVENT SHALL EITHER PARTY OR ITS EMPLOYEES, AGENTS, AFFILIATES, OWNERS OR OFFICERS
BE LIABLE TO THE OTHER PARTY FOR SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, PUNITIVE OR EXEMPLARY DAMAGES, HOWEVER CAUSED, WHETHER
FOR BREACH OF WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE.

 

9.           INDEMNIFICATION

 

9.1          Indemnification by Accelerated.
Accelerated shall indemnify, defend and hold harmless Manufacturer, its Affiliates, and their respective officers, directors, agents,
employees, and shareholders from and against all claims whether such claim is stated as a product liability claim, a strict liability
claim or other similar claims, to the extent such claims on any legal theory relates to or arises from: (a) personal injury or
death of any person from any pharmaceutical product manufactured or sold by Accelerated that incorporates a Product, provided that
this indemnification obligation shall not extend to a claim to the extent such claim is found to have been directly caused by Manufacturer’s
negligence, gross negligence or willful misconduct, or violation of any material applicable local, state, federal, foreign or international
law or regulation, in each case in connection with the manufacture, labeling, packaging, sale, storage or shipment of such Product,
as proven by a final non-appealable judgment, (b) the infringement or alleged infringement of any third-party’s patent, copyright
or trade secret right to the extent such infringement is based upon Accelerated’ s specifications or the design of the products
provided by Accelerated to Manufacturer or the end use or application of a product, or (c) Accelerated’ s negligence, gross
negligence or willful misconduct, or violation of any material applicable local, state, federal, foreign or international law or
regulation, in each case in connection with the manufacture, assembly, design, handling, labeling, packaging, sale, storage or
shipment of devices incorporating any Product, as proven by a final non-appealable judgment. Manufacturer shall: (i) give Accelerated
prompt written notice of any claims for which Manufacturer may seek indemnification from Accelerated; (ii) permit Accelerated to
participate in the defense of the same through its counsel, subject to any applicable privileges; (iii) give relevant information
in its possession relating to such claims; (iv) assist in such defense; and (v) not compromise or settle any such claims without
Accelerated’s written consent.

 

9.2          Insurance provided by Accelerated.
For the clinical development project, Accelerated is obligated to take out an insurance for the test persons which provides sufficient
coverage in the event any test person suffers injuries to life, body or health. Accelerated will include Heraeus as additional
insured under this insurance policy.

 

10.          TERM

 

This Agreement shall commence on the Effective
Date and will continue in full force and effect until completion of the Services, unless terminated as provided in Section 13.

 

11.          TERMINATION AND POST-TERMINATION
OBLIGATIONS

 

11.1       Termination by Mutual Consent.
This Agreement may be terminated at any time by mutual written agreement of the Parties.

 

    Page 6 of 10 

     

    

 

11.2        Optional Termination. This Agreement
may be terminated by either of the Parties without cause by giving the other Party fifteen (15) calendar days’ prior written
notice.

 

11.3        Termination by Accelerated. Accelerated
may terminate this Agreement, effective immediately upon written notice to Manufacturer, in the event of a material breach of this
Agreement (including the breach of any of the representations and warranties contained herein), bankruptcy, loss of commercial
registration or cessation of business, except that in the event of a breach caused by Product quality issues, Accelerated will
provide Manufacturer with notice and a reasonable opportunity to cure by repair or replacement of non-conforming Products with
conforming Products.

 

11.4        Effect of Termination. On termination,
Accelerated’s sole obligation to Manufacturer will be to pay any then-outstanding unpaid fee for Services actually performed
hereunder and to reimburse Manufacturer for then-outstanding reimbursable expense. Manufacturer shall waive any and have no claims
upon Accelerated in respect of any severance or similar compensation in any form. Manufacturer hereby expressly agrees that termination
of this Agreement will not void, invalidate, or otherwise affect Manufacturer’s obligations under Section 6 (Confidentiality).
Manufacturer expressly agrees that the terms of Section 6 will survive expiration or termination of this Agreement.

 

12.          NOTICE TO ACCELERATED

 

12.1        If Manufacturer receives a request
or demand to disclose any books, documents, or records relevant to this Agreement for the purpose of an audit or investigation,
Manufacturer shall notify Accelerated immediately (within two (2) business days after receipt of such request or demand) in writing
of the nature and scope of such request or demand. Manufacturer shall make available to Accelerated, upon written request of Accelerated,
all such books, documents, or records.

 

13.          MANUFACTURER PERSONNEL

 

13.1 Manufacturer shall be solely responsible
for the compensation of its Personnel, including the payment of salary, benefits and employment-related taxes and withholding.
Manufacturer shall be permitted to use subcontractors to provide Services under this Agreement.

 

14.          INTELLECTUAL PROPERTY

 

14.1       Accelerated Intellectual Property.
Manufacturer acknowledges (a) Accelerated’s exclusive right, title and interest in and to Accelerated’s Intellectual
Property; (b) the validity of any and all registrations thereof; (c) that Accelerated is the sole owner of same and all goodwill
relating thereto; and (d) that Manufacturer shall not, by reason of this Agreement or otherwise, acquire any right title or other
ownership therein other than the limited privilege of use contemplated by this Agreement. For these purposes, -Intellectual
Property” means that all trademarks and foreign language equivalents, copyrights and translations of Accelerated copyrights
property, domain names, trademarks and trade names, patents, trade dress, emblems, designs (whether registered or not), insignia,
models and methods of Accelerate, Accelerated’ s Confidential Information and any other intellectual property relating to
Accelerated’ s products or packaging, labeling, advertising and promotional materials used for and/or relating to such products.
Manufacturer agrees that he shall take no steps to challenge or impair Accelerated’s Intellectual Property. Subject to these
restrictions and upon prior written approval by Accelerated of content and format, Manufacturer may indicate on its stationery,
advertising and promotional materials that it is Accelerated’s supplier.

 

    Page 7 of 10 

     

    

 

14.2        Manufacturer Intellectual Property.

 

Accelerated acknowledges that, except as specifically
set forth herein, that all right, title and interest in and to Manufacturer’s Intellectual Property shall be solely and exclusively
vested in Manufacturer and no ownership, interest, right or license is granted to the other Party.

 

15.          GOVERNING LAW AND ARBITRATION

 

15.1        Governing Law. This Agreement will
be governed by and construed in accordance with the substantive laws of Germany without regard to its conflict of law rules.

 

15.2        Emergency Remedies. Notwithstanding
Section 17.2, the Parties acknowledge and agree that that they will have injunctive and other equitable remedies as described
in Section 18.9  (Remedies) below.

 

16.          MISCELLANEOUS

 

16.1       Force Majeure. If the performance
of any obligation under this Agreement by Manufacturer is prevented, restricted, or interfered with by reason of war, revolution,
civil commotion, acts of public enemies, blockade, embargo, strikes, interruption of supply, any law, order, proclamation, regulation,
ordinance, demand, or requirement having a legal effect of any government or any judicial authority or representative of any such
government, which is beyond the reasonable control of the Party affected, then the Party so affected shall, upon giving prior written
notice to the other Party, be excused from such performance (other than the obligation to pay amounts due hereunder) to the extent
of such prevention, restriction, or interference, provided that the Party so affected shall use reasonable commercial efforts to
avoid or remove such causes of nonperformance and shall continue performance hereunder with reasonable dispatch whenever such causes
are removed. Neither Party shall be in default if any delay or failure to perform any obligation hereunder (other than the obligation
to pay amounts due hereunder) that is caused by events beyond such Party’s reasonable control.

 

16.2       Waiver of Compliance. Neither party
shall by mere lapse of time, without giving notice or taking other action hereunder, be deemed to have waived any breach by the
other party of any of the provisions of this Agreement. Further, the waiver by either party of a particular breach of this Agreement
by the other shall not be construed as or constitute a continuing waiver of such breach or of other breaches of the same or other
provisions of this Agreement.

 

16.3       Severability. It is intended that
this Agreement shall not violate any applicable law and the unenforceability or invalidity of any provision, or part thereof, (other
than the provisions obligating Accelerated to make payments to Manufacturer) shall not affect the force and validity of any other
provision and such invalid provisions shall be deemed severed from this Agreement, and, if permissible, be replaced with terms
which as closely as possible approximate the intent of such invalid provisions.

 

16.4       Counterparts. This Agreement may
be executed in any number of counterparts, including electronic or facsimile produced copy, each of which shall be deemed an original
and all of which shall constitute one and the same agreement.

 

16.5       Headings. The headings contained
in this Agreement are for convenience of reference only and do not qualify or affect in any way the meaning or interpretation of
this Agreement.

 

16.6       Construction of Agreement. Each
Party represents that it has carefully read and fully understands the scope and effect of all the provisions of this Agreement,
and that it was offered such period as it deemed necessary to consider it. Consequently, any language deemed to be ambiguous contained
herein shall not be construed in favor of one Party over the other.

 

    Page 8 of 10 

     

    

 

16.7       Relationship. Notwithstanding any
provision hereof, for all purposes of this Agreement each Party shall be and act as an independent contractor and not as partner,
joint venturer, employer, employee or agent of the other and shall not bind nor attempt to bind the other to any contract. Manufacturer
is an independent contractor and is solely responsible for all taxes, withholdings, and other statutory or contractual obligations
of any sort, including, but not limited to, Workers’ Compensation Insurance.

 

16.8       Non-assignment. This Agreement
is personal to Manufacturer and cannot be assigned by Manufacturer or otherwise transferred to any other person or party without
Accelerated’s prior written consent, unless as a part of a sale or transfer of assets to any Manufacturer affiliate. Any
assignment without such consent will be cause for immediate termination of this Agreement by Accelerated. Any other attempts to
transfer will be void. Manufacturer further agrees not to subcontract services under this Agreement, in whole or in part, without
Accelerated’s prior written consent. Manufacturer’s obligations under this Agreement are binding on Manufacturer’s
heirs, legal representatives, administrators, and executors.

 

16.9       Remedies. Notwithstanding and as
an exception to Section17.2 above, the Parties acknowledge and agree that in the event of any breach or threatened breach of Section
6 or the breach of its obligations relating to ownership or use of intellectual property, the other Party will suffer irreparable
damage for which it will have no adequate remedy at law. Accordingly, each Party shall be entitled to seek injunctive and other
equitable remedies to prevent or restrain, temporarily or permanently, such breach or threatened breach, without the necessity
of posting any bond or surety, in addition to any other remedy that such Party may have at law or in equity.

 

16.10     Notices. Notices or communications
to be given under this Agreement shall be provided to the appropriate Party in writing either by personal delivery, overnight delivery
service, confirmed telefacsimile, electronic mail or registered or certified mail, postage prepaid, to the addresses first set
forth above or to such other addresses and to such other persons as either Party may from time to time designate by notice given
as herein provided. Such notices or communications shall be deemed to have been given upon receipt if by personal delivery, five
(5) business days after deposit in the United States mail if sent by first class, registered, or certified mail, postage prepaid,
one (1) business day after delivery if by an overnight delivery service, or upon transmission confirmation if by telefacsimile
or electronic mail.

 

16.11     Entire Agreement. The Parties
hereto acknowledge that this Agreement, together with any Statements of Work attached hereto or executed after the date hereof,
is the complete and exclusive statement of agreement respecting the subject matter hereof and supersedes and renders null and void
any and all agreements and proposals (oral or written), understandings, representations, conditions, and other communications between
the Parties relating hereto and shall constitute the only valid binding and enforceable agreement between them. This Agreement
may be amended only by a subsequent writing that specifically refers to this Agreement. An exchange of email correspondence in
which both Parties agree to a change or addition to the Agreement shall be treated as an agreement in writing for these purposes.

 

    Page 9 of 10 

     

    

 

IN WITNESSETH WHEREOF, the Parties have executed
this Agreement as of the Effective Date.

 

	ACCELERATED
    PHARMA, INC.	 	HERAEUS
PRECIOUS METALS GMBH & Co. KG
	 	 	 	 	 
	By:	/s/
    Michael Fonstein	 	By:	/s/
    Dr. Marcus Hannakam
	Name:	Michael Fonstein	 	Name:	Dr. Marcus Hannakam
	Title:	CEO 5/5/15	 	Title:	Global Head of Marketing and Sales

 

	ACCELERATED PHARMA, INC.	 	HERAEUS PRECIOUS METALS GMBH & Co. KG
	 	 	 	 	 
	By:	/s/ Michael Fonstein	 	By:	/s/ Eberhard Rämisch
	Name:	Michael Fonstein	 	Name:	Eberhard Rämisch
	Title:	CEO 5/5/15	 	Title:	Head of New Sales & Business Development 

        Pharmaceutial Ingredients Business Unit

        Heraeus Precious Metals GmbH & Co. KG

        27.04.2015

 

    Page 10 of 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]